Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 3 1Phase 1/2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3CNS 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 2Meningeal Carcinomatosis 1Glioblastoma 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Interventional × XL647 × Clear all
NCT00364780 2022-05-13

Study of XL647 in Subjects With Non-Small-Cell Lung Cancer

Kadmon Corporation, LLC

Phase 2 Completed
55 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00522145 2022-05-13

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Kadmon Corporation, LLC

Phase 2 Completed
41 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02616393 2022-03-16

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Kadmon Corporation, LLC

Phase 2 Completed
36 enrolled 22 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT02844439 2021-09-22

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Kadmon Corporation, LLC

Phase 2 Completed
40 enrolled 25 charts
CNS

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡